Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

On July 30, 2025, Pfizer (PFE) saw its shares drop by 2.02%, with a trading volume hitting $0.86 billion and ranking 118th in ...

Pfizer in deal with China's 3SBio to license cancer drug candidate Live News Stay up to date with breaking news in business, markets and current affairs, and our in-depth reporting and analysis on the ...

NEW YORK - Pfizer Inc. (NYSE:PFE), a pharmaceutical giant with $62.46 billion in revenue and a market capitalization of $130.76 billion, has secured an exclusive licensing agreement with Chinese ...

3SBio shares jumped 36.4% to HK$19.78 by the afternoon break, compared to an over 1% jump in the Hang Seng index. Pfizer said on Tuesday that it had signed an agreement with 3SBio to license its ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

On July 24, 2025, Pfizer Inc. (NYSE:PFE) finalized the global licensing agreement with 3SBio, Inc. With this agreement, PFE acquired the exclusive rights to develop, manufacture, and commercialize ...

The deal, which excludes China but provides Pfizer with an option for commercialization rights within the country, involves an upfront payment of $1.25 billion to 3SBio.